Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Glaxosmithkline Pharmaceutical advanced 3.21% to Rs 2,879.70 after the company's standalone net profit jumped 34.73% to Rs 260.14 crore on a 6.06% increase in revenue from operations to Rs 966.08 ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck & Co crashed the party.

There are many treatments for endometrial cancer, and the choice of treatment will depend on the extent (stage) of your disease along with other things. Jemperli is a treatment for endometrial cancer.

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

GSK plc announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary ...

Endometrial cancer originates in the endometrium, which is the inner lining of the uterus. Credit: megaflopp/Shutterstock. The European Commission (EC) has approved GSK’s Jemperli (dostarlimab) ...